Dr Reddy was delivering a lecture on the science and promise of the gut microbiome at the CSIR–Indian Institute of Chemical ...

Markets top brokerage firms forecast suggest that Dr Reddys Laboratories will report a net profit of approximately Rs 1,456.5 ...

Emkay's latest report downgrades Dr. Reddy's Labs, citing significant margin misses in Q4FY25 despite higher other income and lower tax rates.

India's Dr Reddy's Laboratories, one of country's largest generic drugmakers, said that it is open to expanding its manufacturing footprint in the key U.S. market as tariff threat looms. "We are more ...

Dr. Reddys Laboratories reported a 22% YoY rise in Q4 net profit to Rs 1,594 crore, exceeding estimates. Revenue grew 20% to ...

Dr. Reddy's (NYSE:RDY) is scheduled to announce Q4 earnings results on Friday, May 9th, before market open. The consensus EPS ...

Dr. Reddy's Laboratories Ltd. closed 18.57% short of its 52-week high of 1,420.20 rupees, which the company achieved on ...

Pharma major Dr Reddy’s Laboratories Ltd’s consolidated net profit increased 21% in the fourth quarter ended March 31, 2025 ...

From Swiggy's widening net loss, Yes Bank's stake sale to Manappuram Finance's impairment charges, these are the important ...

Hyderabad: Dr Reddy's Labs has announced the re-appointment of G V Prasad as Co-Chairman and Managing Director for a period ...

Dr. Reddy's Laboratories Ltd. closed 19.12% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Thank you for joining us today for the Dr. Reddy's earnings conference call covering the quarter and full year ended March 31, 2025. We appreciate your time and participation. Joining us today is the ...